GN Hearing maintains guidance – still predicts 25 percent growth for 2021

Hearing aid company GN Hearing maintains its guidance for 2021 from the firm's presentation of its annual report in February. Thus, it forecasts that its revenue will grow more than 25 percent organically.

Photo: GN Store Nord / PR

Denmark-based company GN Hearing maintains its guidance for 2021, and thus, still envisions organic growth in the 25 percent range and an earnings before interest, taxation and amortization (EBITA) margin at more than 16 percent, which the company communicates in an announcement to the stock exchange on Wednesday morning in a financial update containing preliminary figures for the firm's Q1.

"We still expect that the EBITA margin in a more normalized market in the second half-year of 2021 will improve to reach our goal in the medium-long term at more than 20 percent," GN writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs